From Yahoo Finance: 2025-06-09 09:13:00

AbCellera Biologics Inc. (ABCL) has a bullish thesis with shares at $2.14 on June 2nd, a trailing P/E of 19.92. ABCL is advancing two new molecules, ABCL575 and ABCL635, into clinical trials targeting the OX-40 pathway and NK3R receptor, showing potential for treating various conditions. CEO Carl Hansen sees broad therapeutic applications.

Despite a weak financial position, AbCellera’s platform shows promise in addressing autoimmune disorders, cancers, and infectious diseases. Success in early trials could lead to significant growth and establish the company as a key player in the therapeutic spectrum. Partnering with firms like Eli Lilly and Moderna, AbCellera remains poised for future clinical and commercial success.

While not among the 30 Most Popular Stocks Among Hedge Funds, 17 hedge fund portfolios held ABCL at the end of the first quarter. Despite this, some AI stocks may offer higher returns with lower downside risk. For investors seeking a cheap AI stock with potential benefits from Trump tariffs and onshoring, exploring other options may be worthwhile.

Read more: AbCellera Biologics Inc. (ABCL): A Bull Case Theory